Introduction

Molecular Medicine Reports

1791-2997 1791-3004

D.A. Spandidos

10.3892/mmr.2020.11240

MMR-22-02-1213

Articles

Molecular mechanism of gossypol mediating CCL2 and IL-8 attenuation in triple-negative breast cancer cells

Messeha

Samia S.

Zarmouh

Najla O.

Mendonca

Patricia

Cotton

Carolyn

Soliman

Karam F.A.

Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA

Correspondence to: Dr Karam F.A. Soliman, Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, G134 H New Pharmacy Building, 1415 S. Martin Luther King Boulevard, Tallahassee, FL 32307, USA, E-mail: karam.soliman@famu.edu

082020

15062020

22 2 1213 1226 14102019 28042020

2020

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Chronic inflammation associated with cancer is characterized by the production of different types of chemokines and cytokines. In cancer, numerous signaling pathways upregulate the expression levels of several cytokines and evolve cells to the neoplastic state. Therefore, targeting these signaling pathways through the inhibition of distinctive gene expression is a primary target for cancer therapy. The present study investigated the anticancer effects of the natural polyphenol gossypol (GOSS) in triple-negative breast cancer (TNBC) cells, the most aggressive breast cancer type with poor prognosis. GOSS effects were examined in two TNBC cell lines: MDA-MB-231 (MM-231) and MDA-MB-468 (MM-468), representing Caucasian Americans (CA) and African Americans (AA), respectively. The obtained IC₅₀s revealed no significant difference between the two cell lines' response to the compound. However, the use of microarray assays for cytokine determination indicated the ability of GOSS to attenuate the expression levels of cancer-related cytokines in the two cell lines. Although GOSS did not alter CCL2 expression in MM-468 cells, it was able to cause 30% inhibition in TNF-α-stimulated MM-231 cells. Additionally, IL-8 was not altered by GOSS treatment in MM-231 cells, while its expression was inhibited by 60% in TNF-α-activated MM-468 cells. ELISA assays supported the microarray data and indicated that CCL2 expression was inhibited by 40% in MM-231 cells, and IL-8 expression was inhibited by 50% in MM-468 cells. Furthermore, in MM-231 cells, GOSS inhibited CCL2 release via the repression of IKBKE, CCL2 and MAPK1 gene expression. Additionally, in MM-468 cells, the compound downregulated the release of IL-8 through repressing IL-8, MAPK1, MAPK3, CCDC88A, STAT3 and PIK3CD gene expression. In conclusion, the data obtained in the present study indicate that the polyphenol compound GOSS may provide a valuable tool in TNBC therapy.

gossypol breast cancer gene expression CCL2 IL-8 signaling pathways

Introduction

Cancer evolves through different abnormal molecular signaling pathways, including chronic inflammation events. Dysregulation of the inflammatory process might lead to chronic inflammation that contributes to many diseases, including cancer, cardiovascular, diabetes, lung diseases, Alzheimer's, and autoimmune diseases (1,2). The relationship between cancer and inflammation is well-established (3). Chronic inflammation is a hallmark of tumorigenesis that significantly mediates various stages in cancer, including cellular changes, initiation, promotion, proliferation, survival, invasion, angiogenesis, and metastasis (1), leading to approximately 15 to 20% of all cancer-related deaths worldwide (4).

Meanwhile, breast cancer (BC) is a heterogeneous disease (5) that demonstrated its link to inflammation (4). In the United States, 15% of the diagnosed BC cases are classified as basal-like BC subtype according to the molecular profile (6,7). Triple-negative breast cancer (TNBC) is the most aggressive and metastatic subgroup that comprises up to 75% of the basal-like BC (8,9), and it is known to be more profound among African American (AA) patients than Caucasian American (CA) patients (10). In TNBC cells, the absence of three specific receptors: Estrogen (ER), progesterone (PR) and human epidermal growth factor (Her2/neu) is a difficult challenge in treating the disease (11,12). Even though, TNBC has an initial significant response to many chemotherapy agents (13), approximately 30% of the patients experience poor prognosis and treatment failure after repeated exposure to these agents, leading to a median survival of one year (14).

Chronic inflammation-associated cancer is characterized by the presence of leukocyte infiltration, prominently macrophages that produce chemokines and cytokines (15). These cytokines are the critical mediators of communication between neoplastic cells in the inflammatory tumor microenvironment (16). Particularly in BC, two chemokines, IL-8, and CCL2 regulate tumor angiogenesis (17,18), survival, and metastasis of cancer cells (19). In addition to their chemotactic role, these two chemokines enable the recruitment of other cells, including monocytes, neutrophils, T lymphocytes, and NK cells (20). Under normal conditions, the pro-inflammatory cytokine, tumor necrosis factor-α (TNF-α), mediates the inflammatory pathway and controls inflamed cells (1). In an aggressive BC environment, TNF-α is excessively produced by the tumor-associated macrophages (TAMs) (21,22) and substantially upregulates many genes involved in cancer cell proliferation, invasion, and metastasis (23).

In normal tissue, homeostasis of cell number and rational cell functions are precisely controlled and maintained through the release of growth-promoting signals. Cell signal dysregulation and cell evolvement to the neoplastic state may impair growth suppressor genes that could lead to prolonging proliferative signaling, cell death resistance, angiogenesis, and even triggering invasion and metastasis (24). In the context of cancer, many signaling pathways, including JAK-STAT, MAPK, PI3K-AKT, NF-қB, Notch, and Wnt, have received substantial attention as targets in cancer therapeutic intervention. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is involved in the cellular response to cytokines and play a pivotal role in the growth factor signaling and apoptosis. Impaired JAK-STAT signaling can lead to tumorigenesis, either directly or indirectly (25). The Mitogen-Activated Protein Kinase (MAPK) pathway (also known as ERK pathway) is essential in stimulating survival, proliferation, migration, and cell adhesion through signals transduction from cytokines and growth factors (19). Parallel to the MAPK pathway, the activated phosphoinositide 3-kinase-protein kinase B (PI3K-AKT) pathway mediates cancer cell metabolism and regulates proliferation. Additionally, this pathway activates other signaling pathways, including Wnt and NF-қB (26), which in turn regulates different genes involved in inflammation, cell viability, proliferation, and apoptosis (27) in BC and many others cancer types.

Plant-derived compounds have been thoroughly screened for their potency in preventing and treating cancer (28). Numerous studies have demonstrated the medicinal importance of the polyphenol compound, gossypol (GOSS) (2,20-binaphthalene)-8,80-dicarboxaldehyde, 1,10,6,60,7,70-hexahydroxy-5,50-diisopropyl-3,30-dimethyl, a minor constituent of cotton (Gossypium hirsutum L.) seeds (29–31). GOSS has various biological activities, including antifertility, antiviral, antimicrobial, and antioxidative activity (32). Moreover, the anti-proliferative, anti-metastatic, and apoptotic effects of GOSS have been documentd against several human cancers, including colon, prostate, glioma, adrenal, leukemia (24,33–37), in addition to breast cancer (28,38–40). The drug combination is critical to accomplish a synergistic therapeutic effect (41) and to overcome the resistance mechanisms of many diseases, including cancer (42). GOSS has been found to induce apoptosis in various types of human cancer cells in combination with low doses of dexamethasone (43), doxorubicin (44), taxanes (45), and valproic acid (46).

Many studies have demonstrated the anticancer effect of GOSS in BC, including the TNBC subtype, MDA-MB-231 (MM-231) cells. However, studying the racial perspective of the compound effects on MDA-MB-468 (MM-468), and its gene-related mechanism of action in comparison to MM-231 cells has never been addressed. Moreover, the potential effect of GOSS on the proinflammatory cytokines, IL-8 and CCL2 has not been reported prior to this work. Therefore, the current study is designed to compare the anticancer effect of GOSS on two TNF-α-stimulated human TNBC cell lines: MM-231 and MM-468, representing Caucasian (CA) and African American (AA) women, respectively (47). We hypothesized that GOSS could modulate the expression of genes involved in many cellular signaling pathways that mediate the regulation of diverse cancer-related cytokines/chemokines.

Materials and methods <sec> <title>Materials

The compound GOSS (purity ≥90%) was purchased from Santa Cruz Biotechnology, Inc. Trypsin-EDTA solution 0.25% and Alamar Blue^® (a sterile buffered solution of resazurin fluorescence dye) were purchased from Sigma-Aldrich; Merck KGaA. Dimethyl sulfoxide (DMSO), penicillin/streptomycin, and Dulbecco's Phosphate Buffer Saline (DPBS) were obtained from the American Type Culture Collection. Dulbecco's Modified Eagle Medium (DMEM), heat-inactivated fetal bovine serum (FBS), and cell culture plates were purchased from VWR International (Radnor). TNF-α, Human Cytokine Antibody Array kit (cat. no. AAH-CYT-1000), Human ELISA kits for C-C Motif Ligand 2 [CCL2, also known as monocyte chemoattractant protein-1 (MCP-1), cat. no. ELH-MCP1] and Interleukin-8 (IL-8, also known as CXCL-8, cat. no. ELH-IL-8) were purchased from RayBiotech. TURBO DNA-free™ kit (cat. no. AM1907) was purchased from Life Technologies, Inc. TRIzol^® reagent was purchased from Invitrogen; Thermo Fisher Scientific. An iScript™ cDNA Synthesis kit (cat. no. 170-8891), SsoAdvanced™ Universal SYBR^® Green Supermix (cat. no. 1725271), Human PCR primers (CCL2, IKBKE, IL-8, STAT3, MAPK1, MAPK3, CCDC88A, PIK3CD, and GAPDH) were purchased from Bio-Rad Laboratories, Inc.

Cell culture

The two immortalized TNBC cell models: MM-231 (https://www.atcc.org/products/all/HTB-26.aspx) and MM-468 (https://www.atcc.org/Products/All/HTB-132.aspx), were purchased from ATCC. Both cell lines were grown in 75-cm TC-flasks at 37°C in humidified 5% CO₂ incubator and subculture as required, using trypsin/EDTA (0.25%). The routinely used DMEM growth medium contained 4 mM L-glutamine and was supplemented with 10% FBS (v/v), and 1% penicillin/streptomycin salt solution (100 U/ml and 0.1 mg/ml, respectively). The DMEM experimental medium was the same, except it was phenol-free and was supplemented with 2.5% FBS as previously reported by others (48).

Cell viability assay

In this experiment, cells were incubated overnight at 37°C at a density of 5×10⁴ cells/well in 96-well microplates. GOSS powder was reconstituted in DMSO. Both types of cells were treated for 24 h with 50 ng/ml of TNF-α, in addition to the compound (concentration ranges of 0–100 µM in MM-231 or 0–50 µM in MM-468 cells). Control wells were treated with DMSO at the highest used concentration (<0.1%). Blank wells were treated in the same manner but without cells. Alamar Blue^® was used to determine cell viability, as described in our previous study (49). The fluorescent-fuchsia dye of the reduced resazurin by viable cells was measured at an excitation/emission of 530/590 nm using a Synergy HTX Multi-Reader (BioTek).

Human cytokine/chemokine protein microarray

Cytokine expression microarray analysis was designed based on the data of the cytotoxicity assay. Four flasks for each cell line were incubated overnight with a density of 10×10⁶ cells/75-cm² TC flask using the experimental media with 2.5% FBS. Four flasks for each cell line were incubated overnight with a density of 10×10⁶ cells/75-cm² TC flask using the experimental media with 2.5% FBS. On the next day, the media were discarded, and the cells were treated with 50 ng/ml TNF-α and low concentrations of GOSS that slightly impacted the cell viability. MM-231 cells were treated as follows: TNF-α (50 ng/ml), GOSS (6.25 µM), and TNF-α + GOSS (50 ng/ml + 6.25 µM, respectively). Similarly, MM-468 cells were treated with TNF-α (50 ng/ml), GOSS (5 µM), and TNF-α + GOSS (50 ng/ml + 5 µM, respectively). In both experimental sets, control samples were exposed to only the solvent DMSO at a concentration of <0.1%. After a 24 h exposure period, the cell-free supernatant of each sample was collected, aliquoted, and stored at −80°C for later use. At the same time, the cells from each flask were pelleted and similarly stored at −80°C for RT-qPCR study. For each cell line, a semi-quantitative method using antibody-coated array membranes was established to measure chemokine/cytokine expression in the cell-free supernatants. The assay was established following the manufacturer protocols. Briefly, four membranes were carefully placed in four chamber-incubation trays and blocked with the provided buffer on a shaker for 30 min at RT. After that, the blocking buffer was decanted, and replaced with 1 ml cell-free supernatant from resting, GOSS-treated, TNF-α-stimulated or cotreated cells, and the four membranes were then kept overnight on a low-speed shaker at 4°C. On the following day, the supernatants were removed from each chamber, and the membranes were washed with the kit washing buffers. Next, 1 ml of freshly constituted biotinylated antibody cocktail was pipetted to each membrane and incubated at RT for 2 h, followed by washing with the same wash buffers. The membranes were incubated again for another 2 h with 2 ml of diluted horseradish peroxidase-conjugated streptavidin (HRP-Streptavidin) followed by the final washes. Cytokines intensities on the blots were detected as spots using a chemiluminescence cocktail. The blot images were captured using a Flour-S Max Multiimager (Bio-Rad Laboratories, Inc.), and the spot intensities were measured with the Quantity-One Software (Bio-Rad Laboratories, Inc.). The Excel-based data analysis was established, using the Human Cytokine Array software C1000 (CODE: S02-AAH-CYT-1000) from RayBiotech.

Human CCL2 and IL-8 chemokines ELISA study

Enzyme-Linked Immunosorbent Assay (ELISA) kits were used to measure the protein levels (pg/ml) for both CCL2 and IL-8 chemokines. Briefly, the standard curves, samples, and reagents were prepared at RT for both chemokines. Standards and samples of 100 µl each were incubated with the antibody pre-coated 96-well ELISA microplates for 2.5 h. The supernatant was replaced by 100 µl of the freshly constituted biotinylated antibody for another hour, then removed. Streptavidin solution (100 µl) was added for 45 min, followed by the addition of 100 µl of the substrate reagent for 30-min incubation. Washes were always performed after each step according to the manufacturer's protocol. The reaction was terminated by the addition of 50 µl of a stop-solution, and the intensity for the chemokines and the standard were measured at 450 nm using a Synergy HTX Multi-Reader (BioTek).

RNA isolation and cDNA synthesis

In this assay, the previously-80°C-frozen cell pellets were used, as mentioned above in the Human cytokine/chemokine protein microarray study. The total RNA was extracted from each sample using 1 ml of Trizol^® reagent and sonicated for 30 sec at RT using VirTishear mechanical homogenizer (LabWrench). Subsequently, 200 µl of chloroform was added to each sample, vortexed, incubated at RT for 2–3 min and centrifuged for 15 min at 10,000 × g and 2–8°C. The aqueous phase was separated and mixed with 500 µl of isopropyl alcohol to precipitate the RNA for different samples. The RNA pellets were then reconstituted in approximately 30–50 µl of nuclease-free water to measure the RNA concentration and purity in each sample using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Inc.). Thereafter, the purified RNA was reverse transcribed into cDNA using an iScript™ cDNA Synthesis Kit and PCR run as follows: 46°C for 20 min and 95°C for 1 min.

Reverse transcription-quantitative PCR (RT-qPCR)

In this study, we measured the expression of various genes involved in CCL2 and IL-8 regulation, using qPCR of the Bio-Rad CFX96 Real-Time System (Bio-Rad Laboratories, Inc.) (50). Briefly, the freshly synthesized cDNA (1 µl; 200 ng) was used for each sample in a final volume of 20 µl (10 µl of the 2× real-time Master Mix, 8 µl nuclease-free water, and 1 µl of primer mix). According to the manufacturer's protocol, the PCR run was performed as follows: Reactants were first incubated at 95°C for 2 min, and then 39 cycles of amplification (51) were carried out with each cycle consisting of denaturing at 95°C for 10 sec, annealing at 60°C for 30 sec, and melting curve at 65–95°C for 5 sec. All qPCR reactions were performed in triplicates for each primer. In this experiment, the used PCR primers were compatible with the different genes under investigation and are summarized in Table I. GAPDH was applied as a reference gene to normalize the mRNA levels for genes of interest.

Statistical analysis

The quantitative data for this study were analyzed using GraphPad Prism 6.2 software. All data points were obtained from the average of at least two independent studies and are expressed as the mean ± SEM. For the viability assay, IC₅₀s values were determined by nonlinear regression model of log (inhibitor) vs. normalized response-variable slope on the software with the R2 best fit and the lowest 95% confidence interval. The significance of the difference between each control and its related treatment groups was determined using one-way ANOVA, followed by Bonferroni's multiple comparison tests. A statistical difference was considered significant at P<0.05 and less. For array blots and ELISA studies, independent (unpaired) Student's t-test was used to verify the significance of the difference between TNF-α vs. control groups, or between TNF-α vs. TNF-α + GOSS groups. Quantitative mRNA expression was analyzed using CFX 3.1 Manager software for Bio-Rad Laboratories, Inc. All genes were normalized against the expression of the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and verified with unpaired Student's t-test.

Results <sec> <title>GOSS decreases cell viability in MM-231 and MM-468 TNBC cells

The anticancer effects of GOSS were examined in the presence of 50 ng/ml of TNF-α in both MM-231 and MM-468 cell lines. As indicated in Fig. 1A and B, a highly significant cytotoxic effect (P<0.0001) was detected at all the tested concentrations ranges 12.5–100 µM in MM-231 cells and 1–50 µM in MM-468 cells. The obtained IC₅₀s (19.13±0.32 µM for MM-231 and 23.46±0.43 µM for MM-468) showed a slightly higher response to the compound in MM-231 cells. Based on the viability studies data, optimum doses of GOSS that causes less than 20% cell death and 50 ng/ml of TNF-α were determined for cytokine/chemokine expression study.

GOSS inhibits the release of CCL2 in MM-231 cells and IL-8 in MM-468 cells

To understand the mechanism of the antitumor effects of GOSS on TNF-α-stimulated MM-231 and MM-468 TNBC cells, we measured the expression of different cytokines/chemokines released in the cell-free supernatants in the presence and the absence of GOSS and 50 ng/ml of TNF-α (52). Low concentrations of GOSS that slightly impacted the cell viability were used (6.25 µM in MM-231 cells and 5 µM in MM-468 cells).

The obtained results show that GOSS repressed the expression of two critical chemokines, CCL2 in MM-231 cells and IL-8 in MM-468 cells, as indicated by the red frames on both the maps and the blot arrays. In the cytokine blots, AAH-CYT-6, the expression of the cytokine was scarcely noticeable on most of blots presenting the supernatants of both control and GOSS-treated cells (Fig. 2A and B). High expression of CCL2 was observed in both TNF-α-treated cell lines (Fig. 2C1 and C2). The intensity of the spot was attenuated in MM-231 cells by the effect of 6.25 µM GOSS (Fig. 2D1), the observation that was not showed in MM-468 cells (Fig. 2D2).

Meanwhile, the intensity of IL-8 was low on the blots presenting the supernatants of both control and GOSS-treated cells (Fig. 3A and B). Indeed, TNF-α has increased IL-8 expression in both cell lines, as indicated on the AAH-CYT-7 blots (Fig. 3C1 and C2). The compound GOSS did not reduce the cytokine expression in MM-231 cells (Fig. 3D1). However, an observed decrease was detected in MM-468 cells in the presence of 5 µM GOSS (Fig. 3D2).

Both chemokines, CCL2 and IL-8, were quantified as a percentage relative to their control. TNF-α has induced an 8-fold increase in CCL2 expression in MM-231 cells (P<0.001) (Fig. 4A). The data indicated that the presence of both GOSS and TNF-α significantly attenuated CCL2 by 30% (P<0.01). Similarly, in MM-468 cells (Fig. 4B), a more than 8-fold increase in the expression of IL-8 (P<0. 01) was quantified in TNF-α-stimulated cells and then inhibited by 60% in the presence of GOSS (P<0.05). The results show that the GOSS compound did not attenuate IL-8 expression in MM-231 cells (Fig. 4C), nor CCL2 in MM-468 (Fig. 4D). Also, no changes were detected when we compare the control to the GOSS-treated cells in both chemokines of interest.

We further validated the microarray data for only the significantly attenuated chemokines. Protein expression quantification for CCL2 (pg/ml) and IL-8 (ng/ml) was measured using two independent ELISA assays. Overall, the data for cytokine arrays and ELISA were consistent in both cell lines. The assay indicated a significant increase in CCL2 (P<0.001) and IL-8 (P<0.01) in TNF-α-treated vs. resting cells (Fig. 4E and F). The simultaneous presence of GOSS and TNF-α attenuated the expression of CCL2 by ~40% in MM-231 cells (P<0.001), and IL-8 expression was also reduced by 50% in MM-468 cells (P<0.05).

GOSS alters the expression of genes regulating the release of CCL2 in MM-231 cells and IL-8 in MM-468 cells

RT-qPCR was performed to determine the relevance of our data and to elucidate the mechanism by which GOSS impact CCL2 and IL-8 regulation in MM-231 and MM-468 cells, respectively (Figs. 5 and 6). Profiling the normalized expression of mRNAs in both cell lines provides precise insights into the influence of the compound on signaling pathways-related genes.

The RT-qPCR data presented in Figs. 5A and 6A indicated that mRNAs expressions of CCL2 and IL-8 were consistent with those of cytokine microarray and ELISA protein studies in both MM-231 and MM-468 cell lines, respectively. The mRNA's data showed that both cell lines responded to TNF-α and TNF-α + GOSS. In TNF-α-stimulated MM-231 cells, CCL2 mRNA expression exhibited a highly significant 32-fold up-regulation (P<0.0001) (Fig. 5A and Table II). This gene was dramatically repressed by 80% in the presence of 6.25 µM GOSS (P<0.0001). Furthermore, GOSS repressed two more genes, IKBKE and MAPK1, which are involved in the signaling pathways of TNF-α-induced CCL2 release. IKBKE showed a significant increase in expression of ~11-fold by TNF-α that was repressed to ~53% by GOSS (Fig. 5B and Table II). The detected up-regulation in MAPK1 was non-significant in the TNF-α-stimulated cells. However, GOSS was able to suppress significantly (P<0.0001) its expression by ~39% (Fig. 5C and Table II).

Similarly, in TNF-α-stimulated MM-468 cells, IL-8 mRNA was upregulated by ~65-fold (P<0.0001) followed by 60% downregulation (P<0.001) when combined with 5.0 µM GOSS (Fig. 6A and Table III). Moreover, a significant fold-increase (P<0.01-P<0.0001) was also found in five more genes (Fig. 6B-F and Table III), including MAPK1, MAPK3, CCDC88A, STAT3, and PIK3CD that showed the highest increase (3-fold). GOSS repressed the expression of these five genes by almost 40–50%, as shown in Fig. 6B-F and Table III.

Indeed, the obtained data in this study, including those of the cytokine microarray blots, ELISA, and PCR evaluation, have validated the up-regulation of CCL2 and IL-8 pro-inflammatory proteins and their mRNAs and assured GOSS ability to inhibit both of them.

Discussion

One of the significant goals in anticancer drug development is targeting signaling pathways regulating cancer cells' survival and proliferation through the inhibition of distinctive gene expressions. The present study examined the anticancer mechanism of the natural polyphenol GOSS in two racially different TNBC cell models. The cytotoxic effects of GOSS with a slight but significantly higher response against MM-231 cells than MM-468 TNBC cells indicate possible different mechanistic effects between the two cell lines. However, the effect of gossypol on normal breast cells was not established; a previous study on another cell line indicated the safety of the gossypol at a similar dose (53). This compound repressed the TNF-α-mediated upregulation of the two BC-dominant proinflammatory chemokines (CCL2) in MM-231 and (IL-8) in MM-468. Mechanisms of inhibitions involved the attenuation of mRNA expression of divers, active genes crucial in regulating pivotal signaling pathways. GOSS impacted MAPK, JAK-STAT, and NF-қB pathways in both cell lines, in addition to the PI3K-AKT pathway only in MM-468 (Fig. 7).

The high expression of TNF-α has been reported in BC patients (21). Whether it is endogenous or is administered in a high dose, TNF-α can function as tumor necrosis or tumor-promoting factor, respectively (54). In cancer, the highly expressed TNF-α stimulates the release of many chemokines, including CCL2 and IL-8 (5,55–57), that are highly expressed in cancer.

The most attenuated chemokines, CCL2, and IL-8 have been known to share some common characters. Both chemokines are belonging to a superfamily of small, soluble, and secreted proteins (58). They both are released into the cancer microenvironment by the endothelial cells and fibroblasts (59,60) to activate lymphocytes and macrophages (61,62).

Treating MM-231 cells with TNF-α upregulated the expression of CCL2, a finding that is consistent with previous studies (17,63). In the presence of GOSS (low dose of 6.25 µM), CCL2 expression was dramatically downregulated in the TNF-α-activated cells. Cytokine CCL2 is the most cancer-related member of the CC chemokine family (64). In BC cells, upregulated CCL2 (65) promotes tumorigenesis and metastasis, and its suppression significantly reduced tumor aggressiveness (66). In MM-231 and other malignant tumors, the upregulated CCL2 (51,59) was linked to the decreased survival of TNBC patients (6). Hence, the reduction of CCL2 expression following antibody administration or genetic mutation (67) led to reduced metastasis and enhanced survival (51), which hold promise in treating TNBC (6).

Previous investigations have highlighted the impact of CCL2 on different signaling pathways regulation. CCL2 and its main receptor CCR2 control BC cell survival through MAPK- and Smad3-dependent mechanisms (19). Moreover, in various tissues, CCL2 activates Notch signaling pathway and regulates cancer stem cells (68), which are vital for BC progression (69,70). CCL2 gene silencing in MM-231 led to various consequences, including inhibition of CCL2 expression, decreased cell proliferation, increased necrosis and autophagy, inhibition of self-renewal, and inhibition of the primary and secondary invasion of the TNBC xenograft tumor, and decreases M2 macrophage recruitment (6).

Our current RT-qPCR gene expression analyses indicate that TNF-α significantly increased the mRNA expression of two genes: CCL2 and its gene regulator IKBKE. At the same time, the data obtained show the ability of GOSS to attenuate the expression of these two genes as well as MAPK1. These three genes are involved in many signaling pathways, including the NF-қB, JAK-STAT, and MAPK, which regulate the expression of CCL2. Nevertheless, NF-қB and MAPK signaling pathways are used by both normal and cancer cells dominating these signaling pathways to enhance their survival and invasion (71).

The gene IKBKE (also known as IKKε) is a member of the IKK family of kinases (72). Extensive studies have reported the correlation between IKBKE down-regulation and the decrease of CCL2 release (49,73). Our current data supported these previous findings and interpreted the mechanism of CCL2 inhibition by GOSS. In TNBC cells, the IKBKE gene is expressed in 60% of BC tissue (74) and acts as an oncogene to support cell viability. Furthermore, the up-regulation of IKBKE enhances resistance to anticancer drugs and protects the BC cells from Tamoxifen-induced apoptosis (75). Indeed, IKBKE is an upstream regulator of the transcription factor NF-kB and JAK-STAT pathways, which have been actively involved in the pathogenesis of TNBC (76–79). Expectedly, the silencing of IKBKE in BC cells has been reported to reduce the NF-қB activity and inhibit proliferation, clonogenicity, migration, and invasion (80–84).

GOSS inhibited the expression of MAPK1 (also known as ERK) that was highly expressed in unstimulated cells. The obtained data are consistent with those from previous studies (85,86) that related the lower survival rate in TNBC to highly expressed MAPKs. These serine/threonine protein kinases are involved in various intracellular metabolism, including differentiation, proliferation, apoptosis, and cellular stress responses (87,88). Deregulated ERK signaling pathway leads to uncontrolled cell proliferation and a reduction in apoptosis (89). In MM-231 BC cells, upregulated p38 pathway is linked to the increased proliferation and migration (71) and contribute to cancer cell invasion (90). Therefore, highlighting GOSS effects on MAPKs implies its particularity for TNBC.

Our data indicated that TNF-α-stimulated the release of IL-8 In MM-468 cells, the finding that agrees with a previous study (56). Indeed, a significant positive relationship has been reported between IL-8 release and TNF-α that can synergistically affect cancer initiation and progression (55). The double-functional IL-8 can boost the immunoregulatory ability or alter the cell microenvironment to enhance tumorigenesis (91). The chemokine IL-8 is a member of the CXC chemokine family of multi-functional proinflammatory cytokines (92). IL-8 is highly expressed in many types of tumors and has the ability to promote cancer cell proliferation (93). In BC patients, elevated levels of serum IL-8 is a predictive marker (55,94). Moreover, IL-8 is positively correlated with angiogenesis and metastasis (95) and contributes to multidrug resistance in human BC cells (96). Particularly in TNBC, IL-8 is highly expressed compared with other BC subtypes (97), and it is associated with a poor prognosis (55,92,98). Meaningfully, the poorer prognosis and treatment resistance are linked to IL-8 and its highly expressed receptors, CXCR1 (IL-8R_A) and CXCR2 (IL-8R_B) in BC patients (95,99,100). Therefore, targeting CXCR signaling is considered a promising approach in in-vivo models of BC (101) as it attenuates the distress effect of IL-8 (102). Here, the TNF-α-stimulated IL-8 expression was followed by a substantial attenuation of the chemokine in the presence of only 5 µM of GOSS.

In MM-468 cells, GOSS repressed many highly expressed genes, including IL-8, MAPK1, MAPK3, CCDC88A, STAT3, and PIK3CD. The number and type of the affected genes in MM-468 were divergent from its counterpart mRNA data for MM-231. The repressed genes modulate major signaling pathways, including MAPK, PI3K-AKT, JAK-STAT, and NF-қB. Those oncogenic signaling pathways regulate IL-8 expression and potentiate tumor cell migration or invasion (103,104). The data indicated high expressions of MAPK1 and MAPK3 in unstimulated MM-468 cells; an observation which is consistent with its counterpart MM-231 and agrees with those previously reported findings (85,86). The reported link between IL-8 mRNA stabilization, its protein production, and the MAPKs (105–107) is compatible with GOSS effects in our MM-468 study.

Furthermore, GOSS inhibited the expression of the CCDC88A gene [also known as AKT phosphorylation enhancer (APE), or AKT-binding protein Girdin], that is highly expressed in BC and other types of cancer (108). The gene augmenting the PI3K-AKT signaling pathway and regulate cell migration (109), proliferation, and apoptosis (110). Also, upregulated AKT expression enhances the NF-қB signaling pathway, promoting tumor progression and metastasis (111). GOSS repressed the overexpression of PIK3CD, the gene encoding phosphoinositide 3-kinase (PI3K). The activated PI3K signaling is involved in metabolism and is essential in promoting tumorigenesis and cell proliferation (112–114). In normal cells, PI3K-AKt/mTOR signaling pathways are critical for cell survival and proliferation. Meanwhile, PI3K, AKT, and mTOR proteins are highly upregulated in BC and other cancers. Inhibitors of these kinases are found to induce apoptosis and to synergize the effect of anticancer drugs to inhibit the tumor progression (112–114). Thus, the obtained data indicate GOSS targeting ability of both PIK3CD and CCDC88A by indirectly attenuating NFқB and, consequently, the overexpression of IL-8 in MM-468 BC cells. The mRNA expression inhibition of the signal transducer and activator of transcription3 (STAT3) signifies the GOSS role against BC. STAT3 is a member of the STAT family proteins, and it is highly triggered in more than 50% of BC patients (115). Furthermore, Targeting STAT3 impacts other cancer-associated pro-inflammatory cytokines (116) and many genes linked to apoptosis, proliferation, and angiogenesis (117). Moreover, phosphorylation of STAT3, AKT, and ERK1/2 stimulate BC cells to undergo epithelial-mesenchymal transition, up-regulate the expression of IL-8 and stimulate BC metastasis (104), inhibiting the mRNA expressions of these proteins in MM-468 cells may further elucidate previously reported anticancer mechanisms of GOSS through inhibiting their phosphorylation (37). Thus, inhibiting STAT3 activation by GOSS is a substantial target in treating different types of cancer.

In summary, the comparative effect of gossypol on different cytokines release from TNBC cells has never been reported before. Also, gossypol effects on the aggressive TNBC of MM-468 cells, derived from AA women (118), are not reported. The current study elucidated a novel mechanism targeting TNBC and highlight the possible gene-related signaling pathways. However, lacking protein production assessments, such as using Western blotting, is a limitation in this research and needs further broader range investigation. The polyphenol compound, GOSS, impacts MM-231 and MM-468 cells differently. In MM-231 cells, the compound attenuated the expression of the cytokine CCL2 through influencing its encoding gene, CCL2, as well as two more regulatory genes (IKBKE and MAPK1), which are involved in NF-қB, JAK-STAT, and MAPK signaling pathways. Similarly, GOSS repressed the cytokine IL-8 in MM-468 cells by targeting IL-8 mRNA expression. However, more genes were inhibited by GOSS, including MAPK1, MAPK3, PIK3CD, STAT3, and CCDC88A. These genes are regulating different interactive signaling pathways mediating IL-8 releases such as PI3K-AKT, JAK-STAT, and MAPK. In conclusion, the data obtained in this study indicate that the polyphenol compound GOSS may provide a valuable tool in TNBC therapies.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Institute of Minority Health and Health Disparity (grant nos. U54 MD007582 and P20 MD006738).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

The conceptualization of this study was accomplished by SSM and KFAS. The research methodology was designed by SSM, NOZ, PM, CC and KFAS. Data analysis was conducted by SSM, NOZ, PM, CC and KFAS. Funding acquisition was fulfilled by KFAS. Project administration was performed by KFAS, and study resources were collected by SSM, NOZ, PM, CC and KFAS. Software analysis of data and figures was conducted by SSM, NOZ, PM and CC, and supervision of the research was conducted by KFAS. Writing of the original draft was undertaken by SSM, and writing, review, and editing of the manuscript were carried out by SSM, NOZ, PM and KFAS. All authors read and approved the final manuscript and accept to be responsible for all aspects of the research in ensuring that the accuracy or integrity of any part of the work is properly considered.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Coussens

Werb

Inflammation and cancer

Nature4208608672002

10.1038/nature01322

12490959

Aggarwal

Nuclear factor-kappaB: The enemy within

Cancer Cell62032082004

10.1016/j.ccr.2004.09.003

15380510

Balkwill

Mantovani

Inflammation and cancer: Back to virchow?

Lancet3575395452001

10.1016/S0140-6736(00)04046-0

11229684

Kuper

Adami

Trichopoulos

Infections as a major preventable cause of human cancer

J Intern Med2481711832000

10.1046/j.1365-2796.2000.00742.x

10971784

Balkwill

TNF-alpha in promotion and progression of cancer

Cancer Metastasis Rev254094162006

10.1007/s10555-006-9005-3

16951987

Fang

Yao

Brummer

Acevedo

Alhakamy

Berkland

Cheng

Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment

Oncotarget749349493672016

10.18632/oncotarget.9885

27283985

Sørlie

Perou

Tibshirani

Aas

Geisler

Johnsen

Hastie

Eisen

van de Rijn

Jeffrey

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Proc Natl Acad Sci USA9810869108742001

10.1073/pnas.191367098

11553815

Niemeier

Dabbs

Beriwal

Striebel

Bhargava

Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation

Mod Pathol232052122010

10.1038/modpathol.2009.159

19898421

Anders

Carey

Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer

Clin Breast Cancer2(Suppl 2)S73S812009

10.3816/CBC.2009.s.008

Albain

Unger

Crowley

Coltman

JrHershman

Racial disparities in cancer survival among randomized clinical trials patients of the Southwest oncology group

J Natl Cancer Inst1019849922009

10.1093/jnci/djp175

19584328

Beaumont

Leadbeater

Treatment and care of patients with metastatic breast cancer

Nurs Stand2549562011

10.7748/ns2011.06.25.40.49.c8566

21755793

Fernandez

Cueva

Palomo

Ramos

de Juan

Calvo

García-Mata

García-Teijido

Peláez

García-Estévez

Novel therapeutic approaches to the treatment of metastatic breast cancer

Cancer Treat Rev3633422010

10.1016/j.ctrv.2009.10.001

19883980

Liu

Kumar

Brown

Kannappan

Tawari

Tang

Jiang

Armesilla

Darling

Wang

Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells

Br J Cancer109187618852013

10.1038/bjc.2013.534

24008666

Craig

O'Shaughnessy

Kiefer

Aldrich

Sinari

Moses

Wong

Dinh

Christoforides

Blum

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities

Mol Cancer Ther121041162013

10.1158/1535-7163.MCT-12-0781

23171949

Allavena

Garlanda

Borrello

Sica

Mantovani

Pathways connecting inflammation and cancer

Curr Opin Genet Dev183102008

10.1016/j.gde.2008.01.003

18325755

Candido

Hagemann

Cancer-related inflammation

J Clin Immunol33(Suppl 1)S79S842013

10.1007/s10875-012-9847-0

23225204

Saji

Koike

Yamori

Saji

Seiki

Matsushima

Toi

Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma

Cancer92108510912001

10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K

11571719

Bieche

Chavey

Andrieu

Busson

Vacher

Corre

Guinebretière

Burlinchon

Lidereau

Lazennec

CXC chemokines located in the 4q21 region are up-regulated in breast cancer

Endocr Relat Cancer14103910522007

10.1677/erc.1.01301

18045955

Fang

Jokar

Zou

Lambert

Dendukuri

Cheng

CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms

J Biol Chem28736593366082012

10.1074/jbc.M112.365999

22927430

Perrot-Applanat

Vacher

Toullec

Pelaez

Velasco

Cormier

El Sheikh Saad

Lidereau

Baud

Bièche

Similar NF-kB gene signatures in TNF-α treated human endothelial cells and breast tumor biopsies

PLoS One6e215892011

10.1371/journal.pone.0021589

21754991

Leek

Landers

Fox

Harris

Lewis

Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma

Br J Cancer77224622511998

10.1038/bjc.1998.373

9649140

Wang

Liang

Zen

Molecular mechanisms that influence the macrophage m1-m2 polarization balance

Front Immunol56142014

10.3389/fimmu.2014.00614

25506346

Yin

Chen

Shu

Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells

Biomed Pharmacother634214282009

10.1016/j.biopha.2009.04.032

19564093

Voss

Senft

Lang

Ronellenfitsch

Steinbach

Seifert

Kögel

The pan-Bcl-2 inhibitor (−)-gossypol triggers autophagic cell death in malignant glioma

Mol Cancer Res8100210162010

10.1158/1541-7786.MCR-09-0562

20587533

Bromberg

Stat proteins and oncogenesis

J Clin Invest109113911422002

10.1172/JCI0215617

11994401

Dreesen

Brivanlou

Signaling pathways in cancer and embryonic stem cells

Stem Cell Rev37172007

10.1007/s12015-007-0004-8

17873377

Zubair

Frieri

Role of nuclear factor-kB in breast and colorectal cancer

Curr Allergy Asthma Rep1344492013

10.1007/s11882-012-0300-5

22956391

Zhong

Leong

Lin

Liu

Lin

(−)-Gossypol-enriched cottonseed oil inhibits proliferation and adipogenesis of human breast pre-adipocytes

Anticancer Res339499552013

23482766

Cao

Sethumadhavan

Bland

Isolation of cottonseed extracts that affect human cancer cell growth

Sci Rep8104582018

10.1038/s41598-018-28773-4

29993017

Zhang

Olk

Chemical composition of defatted cottonseed and soy meal products

PLoS One10e01299332015

10.1371/journal.pone.0129933

26079931

Sharifi-Rad

Fokou

PVT

Sharopov

Martorell

Ademiluyi

Rajkovic

Salehi

Martins

Iriti

Sharifi-Rad

Antiulcer agents: From plant extracts to phytochemicals in healing promotion

Molecules2317512018

10.3390/molecules23071751

Wang

Howell

Chen

Yin

Jiang

Gossypol-a polyphenolic compound from cotton plant

Adv Food Nutr Res582152632009

10.1016/S1043-4526(09)58006-0

19878861

Zhang

Liu

Guo

Ling

Roller

Wang

Yang

Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells

Biochem Pharmacol66931032003

10.1016/S0006-2952(03)00248-X

12818369

Pang

Chen

Wang

Liu

(−)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis

Mol Cancer Ther107958052011

10.1158/1535-7163.MCT-10-0936

21372225

Flack

Pyle

Mullen

Lorenzo

Knazek

Nisula

Reidenberg

Oral gossypol in the treatment of metastatic adrenal cancer

J Clin Endocrinol Metab76101910241993

10.1210/jcem.76.4.8473376

8473376

Moon

Kim

Lee

Kim

Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells

Cancer Lett2641922002008

10.1016/j.canlet.2008.01.030

18314260

Benvenuto

Mattera

Masuelli

Taffera

Andracchio

Tresoldi

Lido

Giganti

Godos

Modesti

Bei

(±)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice

Int J Food Sci Nutr682983122017

10.1080/09637486.2016.1236077

27670669

Moon

Choi

Moon

Kim

Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity

Food Chem Toxicol4999910052011

10.1016/j.fct.2011.01.006

21223991

Gilbert

O'Reilly

Chang

Lin

Brueggemeier

Antiproliferative activity of gossypol and gossypolone on human breast cancer cells

Life Sci5761671995

10.1016/0024-3205(95)00243-Y

7596222

Chang

Brueggemeier

Lin

Gossypol inhibits basal and estrogen-stimulated DNA synthesis in human breast carcinoma cells

Life Sci53PL433PL4381993

10.1016/0024-3205(93)90036-3

8255144

Chou

Drug combination studies and their synergy quantification using the Chou-Talalay method

Cancer Res704404462010

10.1158/0008-5472.CAN-09-1947

20068163

Yoshida

Niki

Jyotaki

Sanematsu

Shigemura

Ninomiya

Modulation of sweet responses of taste receptor cells

Semin Cell Dev Biol242262312013

10.1016/j.semcdb.2012.08.004

22947916

Cheng

Zhao

Yang

Effects of gossypol acetate on apoptosis in primary cultured cells from patients with lymphoid leukemia and its synergy with dexamethasone

Zhongguo Shi Yan Xue Ye Xue Za Zhi202292342012(In Chinese)

22541072

Baoleri

Dong

Zhou

Zhang

Xie

Combination of L-gossypol and low-concentration doxorubicin induces apoptosis in human synovial sarcoma cells

Mol Med Rep12592459322015

10.3892/mmr.2015.4127

26238307

Karaca

Atmaca

Uzunoglu

Karabulut

Sanli

Uslu

Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line MCF-7

J BUON144794852009

19810142

Zhao

Pan

Lin

Huang

Cai

Ouyang

The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling

Oncotarget638952389662015

10.18632/oncotarget.5731

26517515

Tate

Rhodes

Segar

Driver

Pounder

Burow

Collins-Burow

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

Breast Cancer Res14R792012

10.1186/bcr3192

22613095

Sato

Beitz

Kato

Yamamoto

Clark

Calabresi

Raymond

Frackelton Jr

Platelet-derived growth factor indirectly stimulates angiogenesis in vitro

Am J Pathol142111911301993

7682762

Messeha

Zarmouh

Mendonca

Alwagdani

Kolta

Soliman

KFA

The inhibitory effects of plumbagin on the NF-kB pathway and CCL2 release in racially different triple-negative breast cancer cells

PLoS One13e02011162018

10.1371/journal.pone.0201116

30059519

Livak

Schmittgen

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method

Methods254024082001

10.1006/meth.2001.1262

11846609

Yamamoto

Omelchenko

Shi

Nuttall

The influence of NF-kappaB signal-transduction pathways on the murine inner ear by acoustic overstimulation

J Neurosci Res87183218402009

10.1002/jnr.22018

19185019

Gallelli

Falcone

Cannataro

Perri

Serra

Pelaia

Maselli

Savino

Spaziano

D'Agostino

Theophylline action on primary human bronchial epithelial cells under proinflammatory stimuli and steroidal drugs: A therapeutic rationale approach

Drug Des Dev Ther112652722017

10.2147/DDDT.S118485

Barba-Barajas

Hernandez-Flores

Lerma-Diaz

Ortiz-Lazareno

Domínguez-Rodríguez

Barba-Barajas

de Celis

Jave-Suarez

Aguilar-Lemarroy

Guevara-Barraza

Bravo-Cuellar

Gossypol induced apoptosis of polymorphonuclear leukocytes and monocytes: Involvement of mitochondrial pathway and reactive oxygen species

Immunopharmacol Immunotoxicol313203302009

10.1080/08923970902718049

19235535

Anderson

Nakada

DeWitte

Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer

Curr Opin Pharmacol43143202004

10.1016/j.coph.2004.04.004

15251122

Ren

Dai

IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients

Adv Clin Exp Med264214262017

10.17219/acem/62120

28791816

John

Jose

Lim

Saunders

Barnes

Mitchell

Belvisi

Chung

Expression and release of interleukin-8 by human airway smooth muscle cells: Inhibition by Th-2 cytokines and corticosteroids

Am J Respir Cell Mol Biol1884901998

10.1165/ajrcmb.18.1.2813

9448049

Grund

Kagan

Tran

Zeitvogel

Starzinski-Powitz

Nataraja

Palmer

Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells

Mol Pharmacol73139414042008

10.1124/mol.107.042176

18252806

Xue

Long

Zhang

Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells

Oncotarget839230392402017

10.18632/oncotarget.16837

28424406

Strieter

Wiggins

Phan

Wharram

Showell

Remick

Chensue

Kunkel

Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells

Biochem Biophys Res Commun1626947001989

10.1016/0006-291X(89)92366-8

2787988

Sticherling

Hetzel

Schroder

Christophers

Time- and stimulus-dependent secretion of NAP-1/IL-8 by human fibroblasts and endothelial cells

J Invest Dermatol1015735761993

10.1111/1523-1747.ep12366023

8409526

Zachariae

Anderson

Thompson

Appella

Mantovani

Oppenheim

Matsushima

Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line

J Exp Med171217721821990

10.1084/jem.171.6.2177

2161898

Krupa

Fol

Dziadek

Kepka

Wojciechowska

Brzostek

Torzewska

Dziadek

Baughman

Griffith

Kurdowska

Binding of CXCL8/IL-8 to mycobacterium tuberculosis modulates the innate immune response

Mediators Inflamm20151247622015

10.1155/2015/124762

26300588

Ueno

Toi

Saji

Muta

Bando

Kuroi

Koike

Inadera

Matsushima

Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer

Clin Cancer Res6328232892000

10955814

Matsushima

Larsen

DuBois

Oppenheim

Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line

J Exp Med169148514901989

10.1084/jem.169.4.1485

2926331

Espinoza-Sanchez

Chimal-Ramirez

Mantilla

Fuentes-Panana

IL-1β, IL-8, and matrix metalloproteinases-1,-2, and −10 are enriched upon monocyte-breast cancer cell cocultivation in a matrigel-based three-dimensional system

Front Immunol82052017

10.3389/fimmu.2017.00856

28337194

Nam

Kang

Suchar

Shimamura

Kohn

Michalowska

Jordan

Hirohashi

Wakefield

Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells

Cancer Res66717671842006

10.1158/0008-5472.CAN-06-0825

16849564

Qian

Zhang

Kitamura

Zhang

Campion

Kaiser

Snyder

Pollard

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

Nature4752222252011

10.1038/nature10138

21654748

Tsuyada

Chow

Somlo

Chu

Loera

Luu

CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells

Cancer Res72276827792012

10.1158/0008-5472.CAN-11-3567

22472119

Koury

Zhong

Hao

Targeting signaling pathways in cancer stem cells for cancer treatment

Stem Cells Int201729258692017

10.1155/2017/2925869

28356914

Pires

DE Amorim

ÍS

Souza

Rodrigues

Mencalha

Targeting cellular signaling pathways in breast cancer stem cells and its implication for cancer treatment

Anticancer Res36568156912016

10.21873/anticanres.11151

27793889

Huth

Santos

Gravina

Resende

Goes

de Lima

Ropert

Upregulation of p38 pathway accelerates proliferation and migration of MDA-MB-231 breast cancer cells

Oncol Rep37249725052017

10.3892/or.2017.5452

28260101

Peters

Liao

Maniatis

IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex

Mol Cell55135222000

10.1016/S1097-2765(00)80445-1

10882136

Bauer

Redmon

Mazzio

Soliman

Apigenin inhibits TNFα/IL-1α-induced CCL2 release through IKBK-epsilon signaling in MDA-MB-231 human breast cancer cells

PLoS One12e01755582017

10.1371/journal.pone.0175558

28441391

Williams

Grosset

Zamorano Cuervo

St-Pierre

Sylvestre

Gaboury

Grandvaux

Detection of IKKepsilon by immunohistochemistry in primary breast cancer: Association with EGFR expression and absence of lymph node metastasis

BMC Cancer173562017

10.1186/s12885-017-3321-6

28532474

Guo

Shu

Esposito

Coppola

Koomen

Cheng

IKK phosphorylation of estrogen receptor α Ser-167 and contribution to tamoxifen resistance in breast cancer

J Biol Chem291228572016

10.1074/jbc.A109.078212

27825095

Berishaj

Gao

Ahmed

Leslie

Al-Ahmadie

Gerald

Bornmann

Bromberg

Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer

Breast Cancer Res9R322007

10.1186/bcr1680

17531096

Shaw

Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines

J Biol Chem27717397174052002

10.1074/jbc.M109962200

11859072

Walker

Nelson

Zou

Chaudhury

Signoretti

Richardson

Frank

Reciprocal effects of STAT5 and STAT3 in breast cancer

Mol Cancer Res79669762009

10.1158/1541-7786.MCR-08-0238

19491198

Marotta

Almendro

Marusyk

Shipitsin

Schemme

Walker

Bloushtain-Qimron

Kim

Choudhury

Maruyama

The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(−) stem cell-like breast cancer cells in human tumors

J Clin Invest121272327352011

10.1172/JCI44745

21633165

House

Grajales

Ozaki

Jordan

Wubneh

Kimble

James

Kim

Annunziata

IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts

BMC Cancer185952018

10.1186/s12885-018-4507-2

29801480

Boehm

Zhao

Yao

Kim

Firestein

Dunn

Sjostrom

Garraway

Weremowicz

Richardson

Integrative genomic approaches identify IKBKE as a breast cancer oncogene

Cell129106510792007

10.1016/j.cell.2007.03.052

17574021

Hutti

Shen

Abbott

Zhou

Sprott

Asara

Hahn

Cantley

Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation

Mol Cell344614722009

10.1016/j.molcel.2009.04.031

19481526

Barbie

Alexe

Aref

Zhu

Zhang

Imamura

Thai

Huang

Bowden

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth

J Clin Invest124541154232014

10.1172/JCI75661

25365225

Qin

Cheng

Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells

Breast Cancer Res12R742010

10.1186/bcr2644

20863366

Bartholomeusz

Gonzalez-Angulo

Liu

Hayashi

Lluch

Ferrer-Lozano

Hortobágyi

High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients

Oncologist177667742012

10.1634/theoncologist.2011-0377

22584435

Seddighzadeh

Zhou

Kronenwett

Shoshan

Auer

Sten-Linder

Wiman

Linder

ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation

Clin Exp Metastasis176496541999

10.1023/A:1006741228402

10919709

Kyriakis

Avruch

Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update

Physiol Rev926897372012

10.1152/physrev.00028.2011

22535895

Cargnello

Roux

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases

Microbiol Mol Biol Rev7550832011

10.1128/MMBR.00031-10

21372320

Samatar

Poulikakos

Targeting RAS-ERK signalling in cancer: Promises and challenges

Nat Rev Drug Discov139289422014

10.1038/nrd4281

25435214

Wen

Hou

Yang

Zhao

Qin

Sun

Teng

Liu

Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling

Cancer Lett4423203322019

10.1016/j.canlet.2018.10.015

30391782

Liu

Tian

Liu

Chen

Han

The CXCL8-CXCR1/2 pathways in cancer

Cytokine Growth Factor Rev3161712016

10.1016/j.cytogfr.2016.08.002

27578214

Benoy

Salgado

Van Dam

Geboers

Van Marck

Scharpé

Vermeulen

Dirix

Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival

Clin Cancer Res10715771622004

10.1158/1078-0432.CCR-04-0812

15534087

Guo

Zang

Cai

Qian

Zhang

Feng

IL8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NFkB pathway in prostate cancer

Mol Med Rep16903590422017

10.3892/mmr.2017.7747

29039490

Snoussi

Mahfoudh

Bouaouina

Ahmed

Helal

Chouchane

Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma

Hum Immunol6713212006

10.1016/j.humimm.2006.03.018

16698420

Zuccari

Leonel

Castro

Gelaleti

Jardim

Moscheta

Regiani

Ferreira

Lopes

Neto Dde

Esteves

An immunohistochemical study of interleukin-8 (IL-8) in breast cancer

Acta Histochem1145715762012

10.1016/j.acthis.2011.10.007

22244449

Kim

Jeon

Lee

Nam

MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells

Oncol Rep35239824042016

10.3892/or.2016.4557

26780941

Kim

You

Jeong

Kim

Nam

Lee

Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells

Phytomedicine5043492018

10.1016/j.phymed.2018.08.004

30466991

Yao

Lin

Chua

Zhu

Wang

Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells

Int J Cancer121194919572007

10.1002/ijc.22930

17621625

Park

Das

Casagrande

Tian

Nothnagel

Chu

Kiefer

Maier

De Angelis

Marassi

Opella

Structure of the chemokine receptor CXCR1 in phospholipid bilayers

Nature4917797832012

10.1038/nature11580

23086146

100

Singh

Simoes

Clarke

Bundred

Targeting IL-8 signalling to inhibit breast cancer stem cell activity

Expert Opin Ther Targets17123512412013

10.1517/14728222.2013.835398

24032691

101

Singh

Simoes

Howell

Farnie

Clarke

Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells

Breast Cancer Res152102013

10.1186/bcr3436

24041156

102

Alfaro

Teijeira

Onate

Pérez

Sanmamed

Andueza

Alignani

Labiano

Azpilikueta

Rodriguez-Paulete

Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)

Clin Cancer Res22392439362016

10.1158/1078-0432.CCR-15-2463

26957562

103

Elliott

Allport

Loudon

Bennett

Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells

Mol Hum Reprod77877902001

10.1093/molehr/7.8.787

11470867

104

Wang

Tang

Cao

Pang

Zhong

Dang

Tang

Huang

Wei

Activation of IL-8 via PI3K/Akt-dependent pathway is involved in leptin-mediated epithelial-mesenchymal transition in human breast cancer cells

Cancer Biol Ther16122012302015

10.1080/15384047.2015.1056409

26121010

105

Lian

Xia

Ung

Khoi

Yoon

Kim

Jung

Carbon monoxide releasing molecule-2 ameliorates IL-1β-induced IL-8 in human gastric cancer cells

Toxicology 361–36224382016

10.1016/j.tox.2016.07.003

106

Singh

Gutman

Radinsky

Bucana

Fidler

Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice

Cancer Res54324232471994

8205546

107

Fernando

Hamilton

Dominguez

David

McCampbell

Palena

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib

Oncotarget742031420442016

10.18632/oncotarget.9662

27248176

108

Jiang

Enomoto

Jijiwa

Kato

Hasegawa

Ishida

Sato

Asai

Murakumo

Takahashi

An actin-binding protein girdin regulates the motility of breast cancer cells

Cancer Res68131013182008

10.1158/0008-5472.CAN-07-5111

18316593

109

Lin

Ear

Pavlova

Mittal

Kufareva

Ghassemian

Abagyan

Garcia-Marcos

Ghosh

Tyrosine phosphorylation of the Gα-interacting protein GIV promotes activation of phosphoinositide 3-kinase during cell migration

Sci Signal4ra642011

10.1126/scisignal.2002049

21954290

110

Fang

Tong

Qiu

Wang

Tong

Girdin regulates the migration and invasion of glioma cells via the PI3K-Akt signaling pathway

Mol Med Rep12508650922015

10.3892/mmr.2015.4049

26151295

111

Romashkova

Makarov

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling

Nature40186901999

10.1038/43474

10485711

112

Jiang

Liu

PI3K/PTEN signaling in tumorigenesis and angiogenesis

Biochim Biophys Acta17841501582008

10.1016/j.bbapap.2007.09.008

17964232

113

Abraham

Chemokine to the rescue: Interleukin-8 mediates resistance to PI3K-pathway-targeted therapy in breast cancer

Cancer Cell227037052012

10.1016/j.ccr.2012.11.012

23238010

114

Hanahan

Weinberg

Hallmarks of cancer: The next generation

Cell1446466742011

10.1016/j.cell.2011.02.013

21376230

115

Darnell

Validating Stat3 in cancer therapy

Nat Med115955962005

10.1038/nm0605-595

15937466

116

Subramaniam

Shanmugam

Perumal

Nachiyappan

Dai

Swamy

Ahn

Kumar

Tan

BKH

Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma

Biochim Biophys Acta183546602013

23103770

117

Rajendran

Shanmugam

Kannaiyan

Goh

Wong

Wang

Khin

Tergaonkar

Kumar

Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo

Cancer Prev Res (Phila)56316432012

10.1158/1940-6207.CAPR-11-0420

22369852

118

Samson

Porter

Hurley

Adams

Eberth

Disparities in breast cancer incidence, mortality, and quality of care among African American and European American women in South Carolina

South Med J10924302016

10.14423/SMJ.0000000000000396

26741869

Figure 1.

Effect of GOSS and TNF-α on the viability of TNF-α-stimulated MM-231 and MM-468 cells. In combination with 50 ng/ml TNF-α, cells were treated for 24 h with GOSS at concentration ranges of (A) 0–100 µM in MM-231 and (B) 0–50 µM in MM-468 cells. On the x-axis, the arrows represent the designated concentrations to be used in the following cytokine expression study. The percentages of cell survival compared with the control were calculated. The data points are presented as the mean ± SEM of three independent studies (n=6 each). **P<0.01, ****P<0.0001. The significance of the difference between the control and treated groups was determined using one-way ANOVA, followed by Bonferroni's multiple comparisons test. P<0.05 was considered to indicate a statistically significant difference. GOSS, gossypol; ns, not significant; TNF-α, tumor necrosis factor α.

Figure 2.

Effect of GOSS on cytokine expression in TNF-α-stimulated triple-negative breast cancer cells. The human protein microarray AAH-CYT-6 was used to measure chemokine/cytokine expression in the cell-free supernatant. (A1-D1) The four blots represent the supernatants of the following MM-231 cell treatments: (A1) Control, (B1) 6.25 µM GOSS, (C1) 50 ng/ml TNF-α and (D1) GOSS + TNF-α-treated. (A2-D2) The four blots represent the supernatants of the following MM-468 cell treatments: (A2) Control, (B2) 5 µM GOSS, (C2) 50 ng/ml TNF-α and (D2) GOSS + TNF-α-treated. Microarray chemiluminescence spotted the changes in only CCL2 cytokine expression that was red-framed on the AAH-CYT-6 array map as well as on all blots. GOSS, gossypol; TNF-α, tumor necrosis factor α.

Figure 3.

Effect of GOSS on cytokine expression in TNF-α-stimulated triple-negative breast cancer cells. The human protein microarray AAH-CYT-7 was established to measure chemokine/cytokine expression in the cell-free supernatant. (A1-D1) The four blots represent the supernatants of the following MM-231 cell treatments: (A1) Control, (B1) 6.25 µM GOSS, (C1) 50 ng/ml TNF-α and (D1) GOSS + TNF-α-treated. (A2-D2) The four blots represent the supernatants of the following cell treatments: (A2) Control, (B2) 5 µM GOSS, (C2) 50 ng/ml TNF-α, and (D2) GOSS + TNF-α-treated. Microarray chemiluminescence determined the changes in only IL-8 chemokine expression that was red-framed on the AAH-CYT-7 array map as well as on all blots. GOSS, gossypol; TNF-α, tumor necrosis factor α.

Figure 4.

Cytokine array quantification of chemokines inhibited by GOSS in TNF-α-stimulated triple-negative breast cancer cell lines. The effect of GOSS on the extracellular cytokine expression was assessed as follows: CCL2 release from (A) MM-231 cells and (D) MM-468 cells, IL-8 release from (B) MM-468 and (C) MM-231 cells. ELISA quantifications (E) for CCL2 released from MM-231 cells and (F) for IL-8 released from MM-468 cells. The normalized data show the cytokine expression in four sets of experimental cell supernatants, namely control, GOSS-treated (6.25 µM in MM-231 cells and 5 µM in MM-468 cells), 50 ng/ml TNF-α-stimulated, and co-treated cells (TNF-α + GOSS). The data are presented as the mean ± SEM of three independent experiments. The dot intensities are expressed as percent relative to control. The significant difference between TNF-α-stimulated cells vs. resting cells (*) or between TNF-α-stimulated vs. TNF-α + GOSS-treated cells (#) groups was determined by an unpaired t-test. P<0.05 was considered to indicate a statistically significant difference. **P<0.01, ***P<0.001, ^##P<0.01 and ^###P<0.001. NS, not significant; GOSS, gossypol; TNF-α, tumor necrosis factor α.

Figure 5.

Effect of GOSS on proinflammatory cytokine-related gene expression determined using reverse transcription-quantitative PCR in TNF-α-stimulated MM-231 cells. GAPDH-normalized data indicated a significant increase in (A) CCL2 and (B) IKBKE mRNA expression in TNF-α-stimulated MM-231 cells compared with control cells. The same genes, as well as (C) MAPK1, were significantly inhibited in the presence of 6.25 µM GOSS. The data points are presented as the mean ± SEM of three independent experiments. The significance of the difference was analyzed by an unpaired t-test. P<0.05 was considered to indicate a statistically significant difference. ****P<0.0001 vs. control; ^####P<0.0001 vs. TNF-α. NS, not significant; GOSS, gossypol; TNF-α, tumor necrosis factor α.

Figure 6.

Effect of GOSS on proinflammatory cytokine-related gene expression in TNF-α-stimulated MM-468 cells according to reverse transcription-quantitative PCR. GAPDH-normalized data indicated a significant increase in six genes in TNF-α-stimulated vs. control cells as follows: (A) IL-8, (B) CCDC88A, (C) MAPK1, (D) MAPK3, (E) PIK3CD and (F) STAT3 genes. The same genes were significantly inhibited in the presence of 5 µM GOSS. The data points are presented as the mean ± SEM of three independent experiments. The significance of the difference between TNF-α-stimulated vs. control cells as well as TNF-α-activated vs. TNF-α + GOSS was analyzed by an unpaired t-test. P<0.05 was considered to indicate a statistically significant difference. **P<0.01 and ****P<0.0001 vs. control; ^##P<0.01, ^###P<0.001 and ^####P<0.0001 vs. TNF-α. GOSS, gossypol; TNF-α, tumor necrosis factor α.

Figure 7.

Schematic diagram illustrating pro-inflammatory genes involved in different signaling pathways that mediate the release of CCL2 and IL-8 in TNF-α-stimulated MM-231 (blue color) and MM-468 (red color) triple-negative breast cancer cells, respectively. In MM-231 cells, the most down-regulated genes by GOSS are CCL2, IKBKE, and MAPK1. In MM-468 cells, the most down-regulated genes are IL-8, CCDC88A, MAPK1 and 3, PIK3CD, and STAT3. GOSS, gossypol; TNF-α, tumor necrosis factor α.

Table I.

List of primers used in reverse transcription-quantitative PCR experiments.

Name	GenBank accession no.	Amplicon context sequence
MCP1/CCL2	NM_002982.4	ACTGAAGCTCGCACTCTCGCCTCCAGCATGAAAGTCTCTGCCGCCCTTCTGT
		GCCTGCTGCTCATAGCAGCCACCTTCATTCCCCAAGGGCTCGCTCAGCCAGA
		TGCAATCAATGCCCCAGTCACCTGCTGTTATAACTTCACCAATAGGAAGATCT
		CAGTGCAGAGGCTCGCGAGCTAT
IL-8	NM_000584.4	GAGCACTCCATAAGGCACAAACTTTCAGAGACAGCAGAGCACACAAGCTTC
		TAGGACAAGAGCCAGGAAGAAACCACCGGAAGGAACCATCTCACTGTGTG
IKBKE	NM_014002.4	GGCTTGGCTACAACGAGGAGCAGATTCACAAGCTGGATAAGGTGAATTTCAG
		TCATTTAGCCAAAAGACTCCTGCAGGTGTTCCAGGAGGAGTGCGTGCAGAA
		GTATCAAGCGTCCTTAGTCACACACGGCAAGAGGATGAGGGTGGTGCACGAG
MAPK1	NM_002745.4	TTCAGCTGGTCAAGATAATGCTTCCCTGGAAAGATGGGCCTGTTAGAAAGCAT
		TTCTGCCAGAATGCAGCCTACAGACCAAATATCAATGGACTTGGTGTAGCCCT
		TGGAATTCAACATAATTTCTGGAGC
MAPK3	NM_002746.3	TCTCCATCAGGTCCTGCACAATGTAGACATCTCTCATGGCTTCCAGGGTGGAC
		GCCCGCAGAATGTCTCGGATGCCGATGACATTCTCATGGCGGAAGCGCAGCA
		GGATCTGGATCTCCCGGAGCGTGCGCTGGCAGTAGGTCTGATGTTCGAAGGG
		GCTGATCTTCTTGATGGCCACGC
CCDC88A	NM_001365480.1	GGAGTTGGGCATTCTGGTTCATGAGTGAGGTACTTTGGGAATTAAGGGTGGA
		ATTTTCAACCTGAAGCTTGGCATTCTGTGTTTGAAGAGTGGTATTCTGTTCTTG
		TAATGACACTGTCTGCCTCTGAAGTGCAAGAATCTGAGCCTGCAAATTATTGT
		TCTGTGTCT
STAT3	NM_139276.2	GGTGTCACACAGATAAACTTGGTCTTCAGGTATGGGGCAGCGCTACCTGGGT
		CAGCTTCAGGATGCTCCTGGCTCTCTGGCCGACAATACTTTCCGAATGCCTCCT
		CCTTGGGAATGTCAGGATAGAGATAGACCAGTGGAGACACCAGGATATTGGT
PIK3CD	NM_005026.4	GCGGCTGGAGTTCGACATCAACATCTGCGACCTGCCCCGCATGGCCCGTCTCT
		GCTTTGCGCTGTACGCCGTGATCGAGAAAGCCAAGAAGGCTCGCTCCACCAA
		GAAGAAGTCCAAGAAGGCGGACTGCCCCATTGCCTGGG
GAPDH	NM_002046.7	GTATGACAACGAATTTGGCTACAGCAACAGGGTGGTGGACCTCATGGCCCAC
		ATGGCCTCCAAGGAGTAAGACCCCTGGACCACCAGCCCCAGCAAGAGCACA
		AGAGGAAGAGAGAGACCCTCACTGCTGGGGAGTCCCTGCCACAC

Table II.

Gene expression changes in MM-231 triple-negative breast cancer.

Control vs. TNF-α			TNF-α vs. TNF-α + GOSS

Target gene	Fold (+)	P-value	Target gene	Inhibition (%)	P-value
CCL2	32.72	<0.0001	CCL2	79.46	<0.0001
IKBKE	10.60	<0.0001	IKBKE	53.06	<0.0001
MAPK1	1.18	0.0648	MAPK1	38.81	<0.0001

The left side of the table presents the genes that were upregulated (+ fold-changes) by 50 ng/ml TNF-α. By contrast, the right side presents the expression of genes that were downregulated (% inhibition) by 6.25 µM GOSS. P<0.05 was considered to indicate a statistically significant difference. GOSS, gossypol; TNF-α, tumor necrosis factor α.

Table III.

mRNA gene expression changes in MM-468 triple-negative breast cancer.

Control vs. TNF-α			TNF-α vs. TNF-α + GOSS

Target gene	Fold (+)	P-value	Target gene	Inhibition (%)	P-value
IL-8	64.6	<0.0001	IL-8	60.78	<0.0001
CCDC88A	2.66	<0.0001	CCDC88A	53.04	0.0013
MAPK1	1.70	<0.0001	MAPK1	51.90	<0.0001
MAPK3	1.61	0.0062	MAPK3	48.61	0.0002
PIK3CD	3.12	<0.0001	PIK3CD	40.70	<0.0001
STAT3	2.47	<0.0001	STAT3	45.28	<0.0001

The left side of the table presents the genes that are upregulated (+ fold-changes) by 50 ng/ml TNF-α. By contrast, the right side presents the expression of genes that are downregulated (% inhibition) by 5 µM GOSS. P<0.05 was considered to indicate a statistically significant difference. GOSS, gossypol; TNF-α, tumor necrosis factor α.